vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Smith Douglas Homes Corp. (SDHC). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $260.4M, roughly 1.1× Smith Douglas Homes Corp.). Smith Douglas Homes Corp. runs the higher net margin — 1.4% vs -45.7%, a 47.0% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs -9.4%). Smith Douglas Homes Corp. produced more free cash flow last quarter ($8.7M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 17.3%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.
GH vs SDHC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $260.4M |
| Net Profit | $-128.5M | $3.5M |
| Gross Margin | 64.6% | 19.9% |
| Operating Margin | -43.0% | 6.5% |
| Net Margin | -45.7% | 1.4% |
| Revenue YoY | 39.4% | -9.4% |
| Net Profit YoY | -15.8% | -14.3% |
| EPS (diluted) | $-1.01 | $0.39 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $260.4M | ||
| Q3 25 | $265.2M | $262.0M | ||
| Q2 25 | $232.1M | $223.9M | ||
| Q1 25 | $203.5M | $224.7M | ||
| Q4 24 | $201.8M | $287.5M | ||
| Q3 24 | $191.5M | $277.8M | ||
| Q2 24 | $177.2M | $220.9M | ||
| Q1 24 | $168.5M | $189.2M |
| Q4 25 | $-128.5M | $3.5M | ||
| Q3 25 | $-92.7M | $2.1M | ||
| Q2 25 | $-99.9M | $2.4M | ||
| Q1 25 | $-95.2M | $2.7M | ||
| Q4 24 | $-111.0M | $4.1M | ||
| Q3 24 | $-107.8M | $5.3M | ||
| Q2 24 | $-102.6M | $3.6M | ||
| Q1 24 | $-115.0M | $3.0M |
| Q4 25 | 64.6% | 19.9% | ||
| Q3 25 | 64.7% | 21.0% | ||
| Q2 25 | 65.0% | 23.2% | ||
| Q1 25 | 63.3% | 23.8% | ||
| Q4 24 | 61.6% | 25.5% | ||
| Q3 24 | 61.1% | 26.5% | ||
| Q2 24 | 59.1% | 26.7% | ||
| Q1 24 | 61.2% | 26.1% |
| Q4 25 | -43.0% | 6.5% | ||
| Q3 25 | -37.3% | 6.6% | ||
| Q2 25 | -45.9% | 7.7% | ||
| Q1 25 | -54.6% | 8.7% | ||
| Q4 24 | -62.4% | 10.4% | ||
| Q3 24 | -61.3% | 14.2% | ||
| Q2 24 | -56.8% | 11.7% | ||
| Q1 24 | -59.2% | 11.3% |
| Q4 25 | -45.7% | 1.4% | ||
| Q3 25 | -35.0% | 0.8% | ||
| Q2 25 | -43.0% | 1.1% | ||
| Q1 25 | -46.8% | 1.2% | ||
| Q4 24 | -55.0% | 1.4% | ||
| Q3 24 | -56.3% | 1.9% | ||
| Q2 24 | -57.9% | 1.7% | ||
| Q1 24 | -68.2% | 1.6% |
| Q4 25 | $-1.01 | $0.39 | ||
| Q3 25 | $-0.74 | $0.24 | ||
| Q2 25 | $-0.80 | $0.26 | ||
| Q1 25 | $-0.77 | $0.30 | ||
| Q4 24 | $-0.90 | $0.50 | ||
| Q3 24 | $-0.88 | $0.58 | ||
| Q2 24 | $-0.84 | $0.40 | ||
| Q1 24 | $-0.94 | $0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $12.7M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $86.7M |
| Total Assets | $2.0B | $557.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $12.7M | ||
| Q3 25 | $580.0M | $14.8M | ||
| Q2 25 | $629.1M | $16.8M | ||
| Q1 25 | $698.6M | $12.7M | ||
| Q4 24 | $525.5M | $22.4M | ||
| Q3 24 | $585.0M | $23.7M | ||
| Q2 24 | $933.7M | $17.3M | ||
| Q1 24 | $1.0B | $32.8M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $86.7M | ||
| Q3 25 | $-354.5M | $82.2M | ||
| Q2 25 | $-305.5M | $80.0M | ||
| Q1 25 | $-250.8M | $76.9M | ||
| Q4 24 | $-139.6M | $73.6M | ||
| Q3 24 | $-60.1M | $68.4M | ||
| Q2 24 | $-1.6M | $62.1M | ||
| Q1 24 | $68.3M | $59.7M |
| Q4 25 | $2.0B | $557.6M | ||
| Q3 25 | $1.3B | $571.6M | ||
| Q2 25 | $1.3B | $570.2M | ||
| Q1 25 | $1.3B | $513.9M | ||
| Q4 24 | $1.5B | $475.9M | ||
| Q3 24 | $1.5B | $460.1M | ||
| Q2 24 | $1.6B | $429.3M | ||
| Q1 24 | $1.7B | $401.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $9.8M |
| Free Cash FlowOCF − Capex | $-54.2M | $8.7M |
| FCF MarginFCF / Revenue | -19.3% | 3.4% |
| Capex IntensityCapex / Revenue | 9.9% | 0.4% |
| Cash ConversionOCF / Net Profit | — | 2.77× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $-36.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $9.8M | ||
| Q3 25 | $-35.4M | $22.8M | ||
| Q2 25 | $-60.3M | $-28.9M | ||
| Q1 25 | $-62.7M | $-34.9M | ||
| Q4 24 | $-64.5M | $5.5M | ||
| Q3 24 | $-51.1M | $22.9M | ||
| Q2 24 | $-94.0M | $39.0K | ||
| Q1 24 | $-30.3M | $-9.3M |
| Q4 25 | $-54.2M | $8.7M | ||
| Q3 25 | $-45.8M | $21.4M | ||
| Q2 25 | $-65.9M | $-31.1M | ||
| Q1 25 | $-67.1M | $-35.9M | ||
| Q4 24 | $-83.4M | $4.8M | ||
| Q3 24 | $-55.3M | $22.3M | ||
| Q2 24 | $-99.1M | $-2.1M | ||
| Q1 24 | $-37.2M | $-9.7M |
| Q4 25 | -19.3% | 3.4% | ||
| Q3 25 | -17.3% | 8.2% | ||
| Q2 25 | -28.4% | -13.9% | ||
| Q1 25 | -33.0% | -16.0% | ||
| Q4 24 | -41.3% | 1.7% | ||
| Q3 24 | -28.9% | 8.0% | ||
| Q2 24 | -55.9% | -1.0% | ||
| Q1 24 | -22.1% | -5.1% |
| Q4 25 | 9.9% | 0.4% | ||
| Q3 25 | 3.9% | 0.5% | ||
| Q2 25 | 2.4% | 0.9% | ||
| Q1 25 | 2.2% | 0.5% | ||
| Q4 24 | 9.4% | 0.2% | ||
| Q3 24 | 2.2% | 0.2% | ||
| Q2 24 | 2.9% | 1.0% | ||
| Q1 24 | 4.1% | 0.2% |
| Q4 25 | — | 2.77× | ||
| Q3 25 | — | 10.70× | ||
| Q2 25 | — | -12.24× | ||
| Q1 25 | — | -13.01× | ||
| Q4 24 | — | 1.33× | ||
| Q3 24 | — | 4.28× | ||
| Q2 24 | — | 0.01× | ||
| Q1 24 | — | -3.12× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
SDHC
| Southeast | $164.7M | 63% |
| Central | $95.8M | 37% |
